Hongshan Li

发表

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Liang Zhao, Hui Zhang, Richard Pazdur, 2015, Clinical Cancer Research.

FDA Approval Summary: Ramucirumab for Gastric Cancer

Huanyu Chen, K. He, P. Keegan, 2015, Clinical Cancer Research.

FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma

R. Pazdur, G. Reaman, Y. Kasamon, 2022, Pediatric blood & cancer.

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma

K. He, P. Keegan, R. Pazdur, 2017, Clinical Cancer Research.

FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma

Huanyu Chen, P. Keegan, R. Pazdur, 2017, Clinical Cancer Research.

Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non-Small Cell Lung Cancer.

Jiang Liu, Yaning Sun, Yaning Wang, 2019, Journal of pharmaceutical sciences.

Quantitative characterization of circadian rhythm of pulmonary function in asthmatic patients treated with inhaled corticosteroids

V. Sinha, Liang Zhao, Yaning Wang, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Exposure-response (E-R) and case-control analyses of ramucirumab leading to recommendation for dosing optimization in patients with gastric cancer.

L. Fashoyin-Aje, P. Keegan, Hong Zhao, 2015 .

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond

K. Goldberg, P. Keegan, Amy McKee, 2017, The oncologist.

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1 high NSCLC.

Jiang Liu, Martha Donoghue, R. Pazdur, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Jiang Liu, P. Keegan, M. Chatterjee, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

P. Keegan, R. Pazdur, Hong Zhao, 2017, Clinical Cancer Research.

FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.

R. Pazdur, M. Theoret, K. Norsworthy, 2022, The oncologist.

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Manash S. Chatterjee, Jiang Liu, P. Keegan, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Quantitative characterization of circadian rhythm of pulmonary function in asthmatic patients treated with inhaled corticosteroids

V. Sinha, Liang Zhao, Yaning Wang, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Association of Time‐Varying Clearance of Nivolumab With Disease Dynamics and Its Implications on Exposure Response Analysis

Y. Wang, C. Liu, H. Li, 2017, Clinical pharmacology and therapeutics.

FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma

Huanyu Chen, P. Keegan, R. Pazdur, 2017, Clinical Cancer Research.

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma

P. Keegan, R. Pazdur, Hong Zhao, 2017, Clinical Cancer Research.

FDA Approval Summary: Oral Azacitidine For Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.

Meng Li, M. Theoret, D. Przepiorka, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.